z-logo
open-access-imgOpen Access
Back to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma
Author(s) -
D’Alessio Antonio,
Rimassa Lorenza
Publication year - 2021
Publication title -
liver cancer international
Language(s) - English
Resource type - Journals
ISSN - 2642-3561
DOI - 10.1002/lci2.24
Subject(s) - atezolizumab , medicine , pembrolizumab , nivolumab , sorafenib , immunotherapy , oncology , bevacizumab , hepatocellular carcinoma , ramucirumab , monoclonal antibody , durvalumab , pd l1 , cancer , cancer research , immunology , antibody , chemotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom